Clinical Trials

Regenxbio Inc. announced that the FDA has granted fast track designation for RGX-202, a one-time gene therapy for treatment of Duchenne muscular dystrophy.

Alzamend Neuro Inc. announced initiation of a phase 1/2a clinical trial for its proprietary immunotherapy vaccineALZN002 to treat mild to moderate dementia associated with Alzheimer’s disease.

Vico Therapeutics announced that the first patient has been dosed in a phase 1/2a study evaluating VO659, an investigational antisense oligonucleotide for Huntington’s disease and spinocerebellar ataxia types 1 and 3.

In this Healio exclusive video, Laura Korb Ferris, MD, discusses the importance of assessing racial and ethnic diversity in phase 3 clinical trials of risankizumab for the treatment of plaque psoriasis.

Astrocyte Pharmaceuticals Inc. announced initiation of a phase 1b study of AST-004, a small molecule adenosine A3/A1 receptor agonist for stroke and traumatic brain injuries that will be evaluated in healthy volunteers.

Healio spoke with Yasha Modi, MD, to discuss research needs in geographic atrophy.

CuraSen Therapeutics Inc. announced positive data from its randomized, double-blind crossover phase 2 study of CST-103/CST-107, which demonstrated improvements in cognition and mood in those with Parkinson’s disease.

Prilenia Therapeutics announced the completion of its global phase 3 study of pridopidine for Huntington’s disease, with topline results expected in the next few months.

Neuraly has announced that its investigational NLY01 did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated Parkinson’s disease.

Treatment with pitolisant demonstrated significant efficacy in reducing excessive daytime sleepiness and cataplexy in children aged 6 years and older, according to research presented in The Lancet Neurology.